Earnings Feed
Start Free
Home/Filings/4/0001140361-13-017688
4//SEC Filing

Goldstein David S. 4

Accession 0001140361-13-017688

CIK 0001375247other
View on SEC.govCompany Profile

Filed

Apr 28, 8:00 PM ET

Accepted

Apr 29, 2:37 PM ET

Size

16.6 KB

Accession

0001140361-13-017688

Insider Transaction Report

Form 4
Period: 2013-04-25
Obagi Medical Products, Inc.OMPI
Goldstein David S.
Executive Vice President
Transactions
  • Disposition to Issuer

    Stock option (right to buy)

    2013-04-25$13.00/sh−60,000$780,000→ 0 total
    Exercise: $11.00Exp: 2016-12-14→ Common stock (60,000 underlying)
  • Disposition to Issuer

    Stock option (right to buy)

    2013-04-25$13.09/sh−20,000$261,800→ 0 total
    Exercise: $10.91Exp: 2018-05-01→ Common Stock (20,000 underlying)
  • Disposition to Issuer

    Stock option (right to buy)

    2013-04-25$14.29/sh−50,000$714,500→ 0 total
    Exercise: $9.71Exp: 2021-11-29→ Common Stock (50,000 underlying)
  • Disposition to Issuer

    Stock option (right to buy)

    2013-04-25$7.75/sh−20,000$155,000→ 0 total
    Exercise: $16.25Exp: 2018-02-27→ Common Stock (20,000 underlying)
  • Disposition to Issuer

    Stock option (right to buy)

    2013-04-25$12.51/sh−50,000$625,500→ 0 total
    Exercise: $11.49Exp: 2020-03-08→ Common Stock (50,000 underlying)
  • Disposition to Issuer

    Stock option (right to buy)

    2013-04-25$11.30/sh−50,000$565,000→ 0 total
    Exercise: $12.70Exp: 2022-05-01→ Common Stock (50,000 underlying)
Footnotes (1)
  • [F1]This stock option immediately vested in full and was converted into the right to receive cash in an amount equal to the product of (A) the total number of shares subject to the option, and (B) the difference between $24.00 minus the exercise price per share of the option, pursuant to the terms of the Agreement and Plan of Merger, dated March 19, 2013, among the issuer, Odysseus Acquisition Corp., Valeant Pharmaceuticals International and Valeant Pharmaceuticals, International, Inc., as amended, and the issuer's 2005 Stock Incentive Plan, as amended, and as approved by the issuer's Compensation Committee.

Documents

1 file

Issuer

Obagi Medical Products, Inc.

CIK 0001375247

→
Entity typeother

Related Parties

1
  • filerCIK 0001382901

Filing Metadata

Form type
4
Filed
Apr 28, 8:00 PM ET
Accepted
Apr 29, 2:37 PM ET
Size
16.6 KB
View on SEC.gov